Black Diamond Director Opts for $12.8K in Stock Over Cash Compensation

Black Diamond Therapeutics Director Prakash Raman acquired 5,526 shares of common stock at $2.33 per share on June 20, 2025, bringing their total direct ownership to 22,519 shares.

Rhea-AI Filing Summary

Black Diamond Therapeutics Director Prakash Raman acquired 5,526 shares of common stock at $2.33 per share on June 20, 2025, bringing their total direct ownership to 22,519 shares.

Key details of the transaction:

• The shares were issued under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy
• The acquisition represents an election to receive stock in lieu of cash compensation for annual services as a non-employee director
• The reported price is based on the closing market price of the company's common stock on June 18, 2025
• The transaction was reported via Form 4 filing, executed by Attorney-in-Fact Brent Hatzis-Schoch

Insider Trade Summary

Grant/Award: 5,526 shares

Grant/Award 1 txn

Insider Raman Prakash

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,526	$2.33	$13K

Holdings After Transaction: Common Stock — 22,519 shares (Direct)

Footnotes (2)

1. F1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of BDTX stock did Director Raman Prakash acquire on June 20, 2025?

According to the Form 4 filing, Director Raman Prakash acquired 5,526 shares of BDTX common stock on June 20, 2025.

What was the price per share for BDTX Director Prakash's stock acquisition?

The shares were acquired at a price of $2.33 per share, based on the closing market price of BDTX's common stock on June 18, 2025.

Why did BDTX Director Raman Prakash receive these shares?

The shares were issued as compensation in lieu of cash payment for annual services as a non-employee director, according to BDTX's Fifth Amended and Restated Non-Employee Director Compensation Policy.

How many BDTX shares does Raman Prakash own after this transaction?

Following this transaction, Raman Prakash directly owns 22,519 shares of BDTX common stock.

What type of ownership does Raman Prakash have in these BDTX shares?

Raman Prakash has direct ownership (D) of the shares, as indicated in Column 6 of Table I in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 04:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

ONE MAIN STREET, 14TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A(1)		5,526	A	$2.33(2)	22,519	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.